Sellas Life Sciences shares surge after the company reports positive late-stage trial results for an experimental cancer vaccine aimed at treating an aggressive form of blood cancer. Quartz and Bloomberg both describe the move as dramatic, with the stock rising as much as roughly a triple and, in one account, reaching a larger percentage spike.
The reporting frames the news around the clinical outcome and what comes next for regulatory steps. Quartz adds that Sellas plans to meet with the FDA and is preparing a biologics license application in the first half of 2027, while Bloomberg emphasizes the late-stage nature of the data and that it is intended to reduce deaths. Seeking Alpha presents the same overall “late-stage trial win” development but provides limited additional detail in the material provided.
Across sources, the key common ground is that positive late-stage data drive the share surge, while the forward-looking timeline and the specific framing of “death risk” versus general “positive results” differ slightly.